Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Two-period, Two-way Crossover Bioequivalence Study of Two (Cytarabine: Daunorubicin) Liposome for Injection in Elderly AML Subjects
Conditions
Interventions
(cytarabine: daunorubicin) liposome for injection
Vyxeos
+2 more
Locations
1
China
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences
Tianjin, China
Start Date
August 25, 2023
Primary Completion Date
April 1, 2025
Completion Date
December 1, 2025
Last Updated
September 21, 2023
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT04628026
NCT06994676
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions